

Stan F J Van De Graaf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9210649/publications.pdf>

Version: 2024-02-01

43
papers

1,208
citations

393982

19
h-index

377514

34
g-index

44
all docs

44
docs citations

44
times ranked

1696
citing authors

#	ARTICLE	IF	CITATIONS
1	Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. <i>Gut</i> , 2018, 67, gutjnl-2017-314548.	6.1	120
2	Impaired uptake of conjugated bile acids and hepatitis b virus pres1 binding in na+ taurocholate cotransporting polypeptide knockout mice. <i>Hepatology</i> , 2015, 62, 207-219.	3.6	116
3	Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice. <i>Hepatology</i> , 2017, 66, 1631-1643.	3.6	100
4	Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. <i>Scientific Reports</i> , 2017, 7, 15307.	1.6	72
5	Current and future therapies for inherited cholestatic liver diseases. <i>World Journal of Gastroenterology</i> , 2017, 23, 763.	1.4	61
6	Homo- and hetero-dimeric architecture of the human liver Na+-dependent taurocholate co-transporting protein. <i>Biochemical Journal</i> , 2012, 441, 1007-1016.	1.7	58
7	Developments in bile salt based therapies: A critical overview. <i>Biochemical Pharmacology</i> , 2019, 161, 1-13.	2.0	56
8	Na+ taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. <i>Hepatology</i> , 2018, 68, 1057-1069.	3.6	50
9	Monitoring bile acid transport in single living cells using a genetically encoded Förster resonance energy transfer sensor. <i>Hepatology</i> , 2013, 57, 740-752.	3.6	43
10	N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2017, 12, e0170419.	1.1	34
11	Amino acid metabolism, transport and signalling in the liver revisited. <i>Biochemical Pharmacology</i> , 2022, 201, 115074.	2.0	32
12	Knockout of the primary sclerosing cholangitis risk gene Fut2 causes liver disease in mice. <i>Hepatology</i> , 2017, 66, 542-554.	3.6	29
13	Analysis of aberrant pre-messenger RNA splicing resulting from mutations in ATP8B1 and efficient in vitro rescue by adapted U1 small nuclear RNA. <i>Hepatology</i> , 2015, 61, 1382-1391.	3.6	28
14	Mechanistic insights into the inhibition of NTCP by myrcludex B. <i>JHEP Reports</i> , 2019, 1, 278-285.	2.6	28
15	Targeting the Four Pillars of Enterohepatic Bile Salt Cycling; Lessons From Genetics and Pharmacology. <i>Hepatology</i> , 2021, 73, 2577-2585.	3.6	26
16	Rescue of defective ATP8B1 trafficking by CFTR correctors as a therapeutic strategy for familial intrahepatic cholestasis. <i>Journal of Hepatology</i> , 2016, 64, 1339-1347.	1.8	24
17	The somatic FAH C.1061C>A change counteracts the frequent FAH c.1062+5G>A mutation and permits U1snRNA-based splicing correction. <i>Journal of Human Genetics</i> , 2018, 63, 683-686.	1.1	24
18	Intestinal Farnesoid X Receptor Activation by Pharmacologic Inhibition of the Organic Solute Transporter $\text{OATP}2$. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 223-237.	2.3	21

#	ARTICLE	IF	CITATIONS
19	NTCP deficiency in mice protects against obesity and hepatosteatosis. <i>JCI Insight</i> , 2019, 4, .	2.3	21
20	Molecular regulation of the hepatic bile acid uptake transporter and HBV entry receptor NTCP. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158960.	1.2	19
21	Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo. <i>Scientific Reports</i> , 2017, 7, 1646.	1.6	17
22	Identification of FDA-approved drugs targeting the Farnesoid X Receptor. <i>Scientific Reports</i> , 2019, 9, 2193.	1.6	16
23	Inhibition of Hepatic Bile Acid Uptake by Myrcludex B Promotes Glucagon-Like Peptide-1 Release and Reduces Obesity. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 451-466.	2.3	15
24	Calnexin Depletion by Endoplasmic Reticulum Stress During Cholestasis Inhibits the Na ⁺ Taurocholate Cotransporting Polypeptide. <i>Hepatology Communications</i> , 2018, 2, 1550-1566.	2.0	13
25	Blocking Sodium Taurocholate Cotransporting Polypeptide Stimulates Biliary Cholesterol and Phospholipid Secretion in Mice. <i>Hepatology</i> , 2020, 71, 247-258.	3.6	12
26	A Compensatory U1snRNA Partially Rescues FAH Splicing and Protein Expression in a Splicing-Defective Mouse Model of Tyrosinemia Type I. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2136.	1.8	12
27	On the Mechanisms of Biliary Flux. <i>Hepatology</i> , 2021, 74, 3497-3512.	3.6	10
28	Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection. <i>Journal of Hepatology</i> , 2022, 76, 319-331.	1.8	9
29	Autophagy “another piece of the puzzle towards understanding primary biliary cirrhosis?”. <i>Liver International</i> , 2014, 34, 481-483.	1.9	7
30	From fatty hepatocytes to impaired bile flow: Matching model systems for liver biology and disease. <i>Biochemical Pharmacology</i> , 2020, 180, 114173.	2.0	7
31	Thiopurines correct the effects of autophagy impairment on intestinal healing “a potential role for ARHGAP18/RhoA. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	7
32	Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	6
33	Differential and organ-specific functions of organic solute transporter 1 and 2 in experimental cholestasis. <i>JHEP Reports</i> , 2022, 4, 100463.	2.6	6
34	The case for combining treatments for primary sclerosing cholangitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 526-528.	3.7	5
35	The Lipid Raft Component Stomatin Interacts with the Na ⁺ Taurocholate Cotransporting Polypeptide (NTCP) and Modulates Bile Salt Uptake. <i>Cells</i> , 2020, 9, 986.	1.8	5
36	An Exon-Specific Small Nuclear U1 RNA (ExSpeU1) Improves Hepatic OTC Expression in a Splicing-Defective spf/ash Mouse Model of Ornithine Transcarbamylase Deficiency. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8735.	1.8	4

#	ARTICLE	IF	CITATIONS
37	OTC intron 4 variations mediate pathogenic splicing patterns caused by the c.386G>A mutation in humans and spfash mice, and govern susceptibility to RNA-based therapies. <i>Molecular Medicine</i> , 2021, 27, 157.	1.9	3
38	Applicability of different cell line-derived dendritic cell-like cells in autophagy research. <i>Journal of Immunological Methods</i> , 2021, 497, 113106.	0.6	2
39	Insufficient evidence for NTCP activity in stellate cells. <i>Gut</i> , 2022, 71, 2140-2141.	6.1	1
40	PS15 - 74. CD1d-restricted NKT cell function prevents insulin resistance in lean mice, and is regulated by adipocytes. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012, 10, 151-151.	0.0	0
41	Corrigendum to "Clinical and genetic analysis of a family with two rare reflex epilepsies" [Seizure " Eur. J. Epilepsy 29 (2015) 90-96]. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2015, 33, 104.	0.9	0
42	Reply. <i>Hepatology</i> , 2020, 72, 1885-1886.	3.6	0
43	Reply. <i>Hepatology</i> , 2022, 76, E58-E58.	3.6	0